Here is the link to my final manuscript: https://docs.google.com/document/d/1DRo2m--Hr9V4lYq8MnboE8rvMq-Y5Hyni1zN0zEZ2GU/edit
Progress report 10/18/11: http://aptamerstream.blogspot.com/2011/10/r50-selection-against-cd105endoglin.html#links
Cell-surface glycoprotein endoglin (CD105) has been identified as a promising marker for proliferation of human endothelial cells. These tumor-associated cells are optimal targets in therapeutic approaches for human cancer and identifying over-expressed cells (1). They may lead to a deeper understanding in angiogenesis and the use of anti-CD105 as a therapeutic agent (2). Aptamers also would be much more affordable than the antibody therapeutics currently available.
Specific Aim: Several components of the receptor complex Transforming Growth Factor (TGF)-β superfamily, and CD105, are shown to strongly bind together in these cells (3). Studies have also shown that inhibition of CD105 expression enhanced the TGF- β ability to suppress growth of cultured endothelial cells (3). In this respect, an aptamer could possibly serve a likewise function to suppress growth and spreading of malignant tumors.
An aptamer selected against CD105 would be useful in diagnosis and treatment of cancer tumors. Identification with this marker and possibly inhibiting the growth of these destructive cells could potentially be a powerful step towards more curative measures.
Raybiotech_Catalog: 228-10388-2, Size: 10µg, Price: $ 189.00